Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions
about
Association between SLCO1B1 -521T>C and -388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysisPharmGKB summary: very important pharmacogene information for RYR1Pharmacogenomics of statins: understanding susceptibility to adverse effectsPersonalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease.ABCB1 C3435T polymorphism and the lipid-lowering response in hypercholesterolemic patients on statins: a meta-analysisMolecular mechanisms of statin intoleranceGenetics of Dyslipidemia.Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug InteractionsSLCO1B1 Polymorphisms and Statin-Induced Myopathy.Characterization of statin dose response in electronic medical records.The role of mitochondria in statin-induced myopathy.Neuromuscular issues in systemic disease.Patients experiencing statin-induced myalgia exhibit a unique program of skeletal muscle gene expression following statin re-challengeAdvances in the Pharmacogenomics of Adverse Drug Reactions.Changes in drug transport and metabolism and their clinical implications in non-alcoholic fatty liver disease.Management of patients with ST-segment elevation or non-ST-segment elevation acute coronary syndromes in cardiac rehabilitation centers.Statin related adverse effects and patient education: a study from resource limited settings.Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.Drug-Induced Mitochondrial Toxicity.Association between statin-induced creatine kinase elevation and genetic polymorphisms in SLCO1B1, ABCB1 and ABCG2.
P2860
Q28070052-D87EADCA-0349-4993-8F27-E7330D98A140Q28074804-5CCA06CC-B988-43C7-B014-6B542DAC234FQ28079822-AA3C0193-210A-4F49-B425-28F3727A320DQ35107992-507E3752-C7BF-4EEF-A77F-C3B64311750CQ35799847-1FEBFB06-07DF-495D-A914-EBB51B8A4256Q36958324-7DEC867C-26F8-42F9-ABDA-B3D83A9C4D8FQ37021351-ABF6B250-EE4D-4F5E-B03C-C89307A5B8C6Q37145705-7E648542-C2EA-4D16-B020-624E0625DEF6Q37410969-435EC0AE-90B9-457C-A2DC-119564830B2AQ37620582-21CB820C-A6A7-424B-A1C6-5F43E04345D1Q38492567-C63DC672-B605-4F09-8649-BDAB8C9A3CBEQ38501865-4B9BC181-9D09-4AB9-BB31-4E02BE6AA002Q38644316-B41EC591-A860-441E-9F7E-954A73A5BDF8Q38663764-A7394ED1-0BC6-45DE-8B8C-8D56AE9DB991Q38737633-E15F7528-D6A3-448D-8563-D8AFD76C57C4Q44564203-C04F5716-590B-4979-95C6-3D85F7C421E7Q47407410-98BF2A7F-587E-4941-8AA2-565D310692DAQ47676842-EC9D9E22-29B5-4F43-B6E7-B9224C496F23Q51538858-3A66EB76-F5CA-4536-9D05-73D97AFB379FQ54373168-AFE51E6A-5946-4EF1-8324-932D2FE83C4F
P2860
Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Individualized risk for statin ...... lenges and potential solutions
@ast
Individualized risk for statin ...... lenges and potential solutions
@en
type
label
Individualized risk for statin ...... lenges and potential solutions
@ast
Individualized risk for statin ...... lenges and potential solutions
@en
prefLabel
Individualized risk for statin ...... lenges and potential solutions
@ast
Individualized risk for statin ...... lenges and potential solutions
@en
P2093
P2860
P356
P1433
P1476
Individualized risk for statin ...... lenges and potential solutions
@en
P2093
QiPing Feng
Russell A Wilke
Tesfaye M Baye
P2860
P304
P356
10.2217/PGS.12.11
P577
2012-04-01T00:00:00Z